Perrigo relaunches generic Transderm Scop
Perrigo is relaunching its generic Transderm Scop (scopolamine 1.5 mg).
"I would like to thank our quality, R&D, operations and regulatory teams as well as our manufacturing partner Aveva - Apotex for their dedication and professional efforts to bring this complex to manufacture product back to market. This relaunch is another example of our commitment and ability to deliver specialized and complex generic products in important treatment categories to patients at more affordable prices," Perrigo executive vice president and president Rx Pharmaceuticals Sharon Kochan said.
The Transderm Scop brand and generics had a market value of roughly $147 million for the 12 months ending August 2019.